Landos Biopharma, Inc.
1800 Kraft Drive
Suite 216
Blacksburg
Virginia
24060
United States
Website: http://landosbiopharma.com/
86 articles about Landos Biopharma, Inc.
-
Landos Biopharma Announces $16.7 Million Private Placement Financing
1/5/2023
Landos Biopharma, Inc. announced a $16.7 million private placement financing from the sale of pre-funded warrants to purchase an aggregate of 30,909,090 shares of its common stock at a price per pre-funded warrant of $0.54 to entities associated with Perceptive Advisors LLC, Landos’ largest stockholder.
-
Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update
11/10/2022
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced financial results for the third quarter ended September 30, 2022, and provided a business update.
-
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
8/11/2022
Landos Biopharma, Inc. today announced financial results for the second quarter ended June 30, 2022, and provided a business update.
-
With Monkeypox, COVID-19, Long COVID symptoms and persistent diseases like cancer and Alzheimer's, the world is dealing with a lot right now. Here's a look at the latest in clinical trial news.
-
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
8/3/2022
Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced positive top-line results from its Phase 1b clinical trial of NX-13, a novel, oral, NLRX1 agonist in development for the treatment of ulcerative colitis (UC) as a once-daily oral therapy.
-
Landos Names Gregory Oakes President and Chief Executive Officer
6/21/2022
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced that Gregory Oakes has been named President and Chief Executive Officer, and has been appointed to the Landos Board of Directors, effective immediately.
-
Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update
5/12/2022
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced financial results for the first quarter ended March 31, 2022, and provided a business update.
-
Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
3/24/2022
Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
-
Landos Biopharma Appoints Roger Adsett to its Board of Directors
3/10/2022
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced that it has appointed Roger Adsett to the Company’s Board of Directors, effective March 8, 2022.
-
Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/15/2021
Landos Biopharma, Inc. announced financial results for the third quarter ended September 30, 2021 and provided a corporate update on its clinical development plans.
-
Landos Biopharma to Host Corporate Update Call
11/11/2021
Landos Biopharma Inc. announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021.
-
Landos Biopharma Announces Leadership Transition
11/8/2021
Landos Biopharma Inc. today announced that Josep Bassaganya-Riera, Ph.D., has stepped down as Chairman, President and Chief Executive Officer, effective immediately.
-
This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.
-
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis
11/2/2021
Landos Biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for LABP-104, a novel, oral, systemically delivered LANCL2 agonist, for the treatment of rheumatoid arthritis (RA).
-
Monday was a big day for LianBio, as the Shanghai-based company launched on the Nasdaq with an impressive $325 million initial public offering (IPO).
-
Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus
10/28/2021
Landos Biopharma, Inc. today announced the Company has dosed the first subject in a Phase 1 study of LABP-1
-
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
10/11/2021
Landos Biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for LABP-104 or the treatment of systemic lupus erythematosus (SLE).
-
Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor’s Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism
10/6/2021
Landos Biopharma, Inc. today announced the publication of a peer-reviewed article titled “First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of the LANCL2 pathway in psoriasis” in Scientific Reports.
-
Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual)
9/27/2021
Landos Biopharma, Inc., a late-clinical-stage biopharmaceutical company utilizing its LANCE® advanced A.I. platform to develop novel therapeutics for patients with autoimmune diseases, announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will participate in the Truist Securities CEO Fireside Chat Series.
-
Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn’s Disease with the Icahn School of Medicine at Mount Sinai
9/20/2021
Landos Biopharma, Inc. announced a research collaboration with the Icahn School of Medicine at Mount Sinai to conduct a Phase 2 trial of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, in patients with moderate-to-severe Crohn’s disease.